Riktkurs.nu
EN | SV
Stockholm Stock Exchange | Mid Cap
Xvivo Perfusion
+0.81%
-
HandelsbankenDNB CarnegiePareto SecuritiesSEB EquitiesSEBDanske BankDNBDanske Bank MarketsDNB MarketsCarnegieBryan Garnier

Latest Price Target For Xvivo Perfusion

Upside:
+0.81%
AnalystPrice TargetDate
Handelsbanken300 SEKOct -25

All Price Targets For Xvivo Perfusion

AnalystPrice TargetDate
Handelsbanken300 SEKOct -25
DNB Carnegie300 SEKOct -25
Pareto Securities280 SEKOct -25
SEB Equities610 SEKOct -24
SEB600 SEKJul -24
Danske Bank560 SEKJul -24
DNB468 SEKApr -24
Danske Bank Markets405 SEKApr -24
DNB Markets418 SEKJan -24
Carnegie350 SEKJan -24
Bryan Garnier340 SEKNov -23

About The Company

XVIVO is a medical technology company firmly rooted within medical science with more than 20 years of experience in the transplantation area.
Xvivo Perfusion